Search

Your search keyword '"Kahl, Steven D."' showing total 118 results

Search Constraints

Start Over You searched for: Author "Kahl, Steven D." Remove constraint Author: "Kahl, Steven D."
118 results on '"Kahl, Steven D."'

Search Results

1. Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery

2. Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP)

3. Insulin exits skeletal muscle capillaries by fluid-phase transport

4. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

7. Preclinical Characterization of Once Weekly Basal Insulin Fc (BIF)

12. Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle

13. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle

16. Insulin-XTEN® Exhibits a Size-Dependent Alteration in Tissue Action in Rats

17. Structural basis for GPR40 allosteric agonism and incretin stimulation

18. Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus

19. A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes

20. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)

21. Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery.

22. Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus

23. Disulfide as a Constraint to Build Super Potent and Selective Melanocortin-4 Receptor (MC4R) Agonists

24. Discovery and Optimization of β-MSH Derived Melanocortin-4 Selective Agonists

25. Discovery of a Novel Series of Orally Active Nociceptin/Orphanin FQ (NOP) Receptor Antagonists Based on a Dihydrospiro(piperidine-4,7′-thieno[2,3-c]pyran) Scaffold

26. Association of dystrophin and integral membrane glycoprotein

27. Development of LC-MS/MS-Based Receptor Occupancy Tracers and Positron Emission Tomography Radioligands for the Nociceptin/Orphanin FQ (NOP) Receptor

28. Discovery of Aminobenzyloxyarylamides as κ Opioid Receptor Selective Antagonists: Application to Preclinical Development of a κ Opioid Receptor Antagonist Receptor Occupancy Tracer

29. Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity

30. Potent and selective MC-4 receptor agonists based on a novel disulfide scaffold

31. Discovery of a β-MSH-Derived MC-4R Selective Agonist§

33. Synthesis and Structure−Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

35. In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog▪

36. Discovery of a Novel Seriesof Orally Active Nociceptin/OrphaninFQ (NOP) Receptor Antagonists Based on a Dihydrospiro(piperidine-4,7′-thieno[2,3-c]pyran) Scaffold.

47. Design of Signal Windows in High Throughput Screening Assays for Drug Discovery.

48. Validation of a High Throughput Scintillation Proximity Assay for 5-HydroxytryptaminelE Receptor Binding Activity.

Catalog

Books, media, physical & digital resources